Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

Inclusion Criteria: * Completion of the parent study (STU-2020-1339) * Able to provide informed consent * Absence of donor specific antibodies * Stable renal function (eGFR\>40mL/min for 3 months prior to enrollment) Exclusion Criteria: * Female participant who is pregnant, lactating or planning pregnancy during the course of the trial * Significant hepatic impairment * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial * Proteinuria \> 0.5 g/g creatinine on spot urine sample within 3 months of enrollment